Physician

Muhammad Hassaan Imam, MD

According to 2025 Medicare claims, Muhammad Imam, MD (NPI: 1336466622) practices hematology/oncology in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Orange, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32789-2988.

Imam's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 634 traditional Medicare patients, billed 211,878 HCPCS/CPT codes, and received $4,765,927 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,891 prescription claims across 384 beneficiaries totaling $6,232,934 in drug costs, led by Revlimid (Lenalidomide). 2023 DME data shows 65 claims. Open Payments data shows 68 records totaling $3,158. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $321,613 to $4,765,927. Similarly, Part D prescription costs have risen steadily, from $20,985 to $6,232,934. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	N/R	N/R	N/R
2016	246	15,209	$321,613
2017	645	87,660	$1,606,073
2018	891	222,112	$3,386,866
2019	883	211,150	$4,022,290
2020	728	237,007	$4,189,529
2021	831	213,416	$4,095,218
2022	722	204,939	$3,834,031
2023	609	185,486	$3,704,336
2024	634	211,878	$4,765,927

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	19	54	$20,985
2016	62	111	$147,455
2017	150	612	$448,465
2018	231	1,162	$1,730,154
2019	276	1,559	$3,562,614
2020	267	1,812	$4,229,492
2021	304	2,016	$3,553,396
2022	310	2,186	$4,678,715
2023	310	2,330	$4,290,443
2024	384	2,891	$6,232,934

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	32	$8,123
2019	N/R	N/R	N/R
2020	N/R	63	$4,124
2021	N/R	181	$74,470
2022	N/R	N/R	N/R
2023	N/R	65	$13,617
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	296	818	$96
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	274	360	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	350	678	$13
36415	Insertion of needle into vein for collection of blood sample	505	1,703	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	506	1,751	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	50	1,400	$895,057
Pomalyst	Pomalidomide	36	1,008	$685,368
Verzenio	Abemaciclib	36	1,008	$550,030
Brukinsa	Zanubrutinib	42	1,237	$473,966
Truqap	Capivasertib	18	504	$411,918

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	67	$1,876	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	1	$1,283	Amgen Inc.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Muhammad Hassaan Imam, MD?

Tedicare shows public-source Medicare data for Muhammad Hassaan Imam, MD (NPI 1336466622), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Muhammad Hassaan Imam, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Muhammad Hassaan Imam, MD?

Muhammad Hassaan Imam, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Muhammad Hassaan Imam, MD have Open Payments data?

Muhammad Hassaan Imam, MD has 68 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.